Investor Newsletter

Issue 12 2023

MicroPort®



MicroPort® NeuroTech™ Receives Approval for Tubridge® in Brazil

MicroPort® NeuroTech™ has recently received approval for its Tubridge® Vascular Reconstruction Device (Tubridge®) from the Brazilian National Health Surveillance Agency (ANVISA).

Tubridge® is a dense-mesh stent applying the concept of flow diversion therapy, specifically designed for treating large or giant wide-necked complex intracranial aneurysms. Its unique structure, braided with 48/64 wires of nitinol alloy, ensures conformability and radiopacity of the product, while providing excellent wall-apposition and flexibility in pore deformation. Utilizing the principles of hemodynamics, Tubridge® diverts the blood flow in the aneurysm reducing impact on the aneurysm wall. This promotes endothelial cell growth along the stent's scaffold, gradually repairing the aneurysm neck and treating the aneurysm, thereby eliminating the risk of aneurysm rupture.

Tubridge® previously obtained approval in China in March 2018 and in Argentina in August 2023. In the future, MicroPort® NeuroTech™ will continue to invest in product innovation and technological research and development, aiming to provide a comprehensive solution for patients with cerebrovascular diseases across the globe.

MicroPort

MicroPort® NeuroTech™ Completes NUMEN® Clinical Implantations In Japan

Recently, MicroPort® NeuroTech™ announced that the NUMEN™ Coil Embolization System (NUMEN™) completed its first batch of clinical implantations in Japan on 10 October. Within three weeks following this announcement, 28 procedures were successfully carried out in 22 Japanese hospitals, receiving positive feedback overall. Adding to this achievement on October 1, NUMEN™ received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for inclusion in public medical insurance.

To date, both NUMEN™ and the Numen FR™ Detachment System have secured approval in China, the EU, the USA, Korea, Brazil, and Japan. They have successfully completed clinical implantation in several countries across Asia-Pacific, North America, and Europe. The recent achievement in Japan marks NUMEN™'s introduction into the 16th country or region. Its inclusion in Japan's medical insurance system means NUMEN™ can benefit more local patients while significantly reducing financial burden. This is a significant step in NeuroTech™'s ongoing effort to expand global markets.

MicroPort® NeuroTech™ continues to enhance its business operations and advance medical R&D. Looking ahead, MicroPort® NeuroTech™ aims to provide more comprehensive solutions for patients worldwide suffering from cerebral vascular diseases.

VitaFlow®'s 7-Year Follow-Up Data Presents at PCR London Valves

Recently, evidence-based data from the VitaFlow® Transcatheter Aortic Valve (VitaFlow®), developed by MicroPort® CardioFlow, were revealed on PCR London Valves, a leading global event on structural heart diseases. These findings highlight VitaFlow®'s exceptional long-term clinical performance.



Characteristics	N=110	Characteristic	N=110
Mean Age – Year	77.73	COPD	24/110
Male Sex	60/110	Liver Disease	3/110
Mean STS Score	8.84	Renal Insufficiency	14/110
Coronary Artery Disease	62/110	Diabetes Mellitus	31/110
Hypertension	59/110	Cerebral Vascular Disease	24/110
Previous Myocardial Infarction	6/110	Bicuspid Aortic Valve Non-bicuspid Aortic Valve	42/110 68/110
Previous PCI	14/110	LVEF	57.22±12.00%
Peripheral Vascular Disease	45/110	Effective Orifice Area – cm^2	0.64±0.19
Angina CCS Classes II-IV	20/110	Mean AV Gradient - mmHg	60.41±19.40
Previous CABG	0/110		

Professor Angela Mclnerney from Galway University Hospitals, Ireland, highlighted that, "The mixed-density stent design of VitaFlow Liberty® provides better radial support. Its double-layer PET skirt design also effectively reduces the incidence of postoperative paravalvular leak. During the 12-month follow-up, patients treated with VitaFlow Liberty® showed very low transvalvular pressure gradients. Moreover, due to its exceptional flexibility, the valve maintained good coaxiality and stability during deployment."

At the conference, CardioFlow also showcased a booth displaying VitaFlow Liberty® and VitaFlow® III Retrievable Steering Delivery System. They announced the imminent launch of clinical studies targeting European patient groups and the expectation of obtaining CE certification for VitaFlow Liberty® in the near future. The clinical data gathered post-approval will provide significant evidence-based support for the subsequent expansion of the valve system's indications.

MicroPort

MicroPort® MedBot™'s SkyWalker™ Robot's Comparable Performance In China

On November 14, One-year follow-up data from a clinical study by MicroPort® MedBot™'s SkyWalker™ in primary total knee arthroplasty (TKA) showed that the SkyWalker™ robot performed comparably to the field's leading robot in terms of the accuracy of lower limb alignment, operation time, estimated blood loss, and results of postoperative clinical and functional knee assessment at 6-month and 1-year follow-ups.

Postoperative follow-up at 6 months and 1-year showed no significant differences in key metrics, including the range of motion (ROM), Knee Society Score (KSS), the Western Ontario McMaster University Osteoarthritis Index (WOMAC), and visual analogue scale (VAS). All patients exhibited good incision healing, with no exudation of the nail hole, aseptic loosening of the prosthesis, periprosthetic infection, or periprosthetic fracture in the SkyWalker™ group.

While continuously enhancing product performance, the MicroPort® team is dedicated to providing comprehensive professional services, including ongoing reinforcement of clinical education and training, customer support, and clinical assistance.



MicroPort

MicroPort EP's TrueForce™ Ablation Catheter Finishes Clinical Application

On 27 October, two atrial fibrillation treatments and one atrial flutter treatment were successfully performed by Professor Emin from Heart Rhythm Management Center at Dokuz Eylül University using the FireMagic™ TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter) and the latest version of the Columbus™ 3D EP Navigation System (Columbus™ V3), developed by MicroPort EP. This marked the first clinical application of the TrueForce™ Ablation Catheter in Turkey.

During the procedure, Professor Emin highly praised the performance of the TrueForce™ Ablation Catheter, noting its ability to sensitively detect minor pressure changes with real-time, accurate, and stable force feedback. He also commended its comfortable and easy-to-grip handle, as well as its excellent torque control.

Professor Emin utilized the Smart Label auto-mapping feature of Columbus™ V3 throughout the procedures. He indicated that when combined with the catheter's real-time distance measurement capabilities at the tip, it allowed for more precise placement of Smart Label ablation points, thereby reducing the likelihood of GAP occurrences.In the modeling phase with Columbus™ V3, Professor Emin conducted a detailed comparison between the RTM modeling of the TrueForce™ Ablation Catheter with the latest software and its movements under X-ray. Furthermore, members of Professor Emin's team experienced the RTM Toolbar feature in the latest software version for the first time. Following the procedure, Professor Emin expressed enthusiasm to apply MicroPort EP's products in diverse complex cases.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com